On September 8, 2022, Harmonic Discovery, a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, announced its launch with $8 million in seed funding. The round was led by Innovation Endeavors with participation from Fifty Years, Y Combinator, Boom Capital, Caffeinated Capital, and select angel investors. Wilson Sonsini Goodrich & Rosati advised Harmonic Discovery on the launch and seed funding round.

Many drugs exert their effect through multiple modes of action which is a well-established phenomenon known as polypharmacology. The pharmaceutical industry has historically focused on finding drugs optimized to engage specific single targets, however, Harmonic Discovery's fully integrated kinase drug discovery platform aims to challenge this paradigm. Founders of the company are building a machine learning-first infrastructure that integrates several aspects of kinase drug discovery. The company's models learn from the topology of atoms and bonds that make up a kinase drug, to the three-dimensional ins and outs of kinase structure, all the way up to the dynamic cellular environments of disease driven by kinases. By spanning multiple disciplines, including systems biology, cheminformatics, medicinal chemistry, and machine learning, Harmonic Discovery believes it can develop novel therapies across diseases such as cancer and autoimmune disorders.

The Wilson Sonsini team that advised Harmonic Discovery included Megan Baier, Matt Bresnahan, Meg Burton, and Sarah Won.

For more information, please see Harmonic Discovery's press release.